Endobronchial valve treatment of destructive multidrug-resistant tuberculosis
| Autor: | A Levin, S Sklyuev, I Felker, E Tceymach, D Krasnov |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Tuberculosis Adolescent medicine.medical_treatment Antitubercular Agents Atelectasis Drug resistance 030204 cardiovascular system & hematology law.invention Young Adult 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Randomized controlled trial law Drug Resistance Multiple Bacterial Internal medicine Tuberculosis Multidrug-Resistant medicine Humans Lung Chemotherapy business.industry Endobronchial valve Prostheses and Implants Original Articles Middle Aged medicine.disease Treatment Outcome Infectious Diseases medicine.anatomical_structure 030228 respiratory system Drug Therapy Combination Female business Follow-Up Studies |
| Zdroj: | The International Journal of Tuberculosis and Lung Disease. 20:1539-1545 |
| ISSN: | 1815-7920 1027-3719 |
| Popis: | BACKGROUND: In accordance with the existing hypothesis, the application of an endobronchial valve (EbV) leads to selective curative atelectasis of the affected part of the lung, contributing to early closure of cavities. OBJECTIVE: To assess the effect of EbV treatment on the course of tuberculosis (TB). METHODS: We compared the efficacy of EbV treatment and complex second-line treatment in treating patients with destructive pulmonary multidrug-resistant TB (MDR-TB). Bacteriological conversion and closure of cavities were selected as criteria to assess the effectiveness of EbV application. A total of 102 patients with destructive MDR-TB were enrolled into the study and randomly divided into two groups: 49 patients had an EbV installed (intervention group) and 53 patients received complex second-line treatment (control group). Complex chemotherapy was administered to both groups throughout the study period. RESULTS: The cure rate in the short- and long-term follow-up periods in the intervention group was shown to be much higher, 95.9% by bacteriological conversion and 67.3% by cavity closure. On comparison with the control group, this was respectively 37.7% and 20.7% (P < 0.0001). CONCLUSIONS: The application of EbV treatment can significantly improve the effectiveness of second-line chemotherapy regimens in MDR-TB patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|